Sergio Perez Beracasa, MD
Interventional Cardiology · Montgomery, ALNPI 1861832321
Payments from drug & device makers
What this record shows
This record is dominated by grants: $21,000 of the $24,865 with a category attached, or 84.5%. Medtronic accounts for 87.4% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2020 at $21,442 and has fallen 99.4% since, to $124 in 2025.
Across 130 payments — averaging $191.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$22K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$401
- Pfizer$299
- Johnson & Johnson$280
- Edwards Lifesciences$206
- Akcea Therapeutics, Inc.$204
- plus $2K from 22 others
What the payments were for
- Grants$21,00084%
- Food & beverage$3,72515%
- Education$1401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 13 | $21,726 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $401 |
| Pfizer | 15 | $299 |
| Johnson & Johnson | 15 | $280 |
| Edwards Lifesciences | 3 | $206 |
| Akcea Therapeutics, Inc. | 10 | $204 |
| E.r. Squibb & Sons, L.L.C. | 10 | $178 |
| Abbott | 2 | $170 |
| Alnylam Pharmaceuticals Inc. | 3 | $145 |
| AstraZeneca | 2 | $143 |
| Abiomed | 1 | $105 |
| Amgen | 6 | $101 |
| Novo Nordisk | 5 | $99 |
| Actelion Pharmaceuticals US, Inc. | 1 | $96 |
| Siemens Medical Solutions USA, Inc. | 1 | $92 |
| Novartis | 5 | $83 |
| Boston Scientific | 5 | $77 |
| Sanofi-aventis U.S. LLC | 4 | $72 |
| Merck | 4 | $70 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $65 |
| Asahi Intecc USA, Inc. | 2 | $65 |
| Boehringer Ingelheim | 3 | $52 |
| United Therapeutics Corporation | 2 | $45 |
| Irhythm Technologies, Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Teleflex LLC | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Bayer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,865 in reported general payments places this provider in the 80th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 137 | $120,100 |
| EntrestoSacubitril/Valsartan | 44 | $54,219 |
| XareltoRivaroxaban | 57 | $52,788 |
| FarxigaDapagliflozin Propanediol | 56 | $49,358 |
| JardianceEmpagliflozin | 20 | $19,991 |
| Repatha SureclickEvolocumab | 34 | $19,681 |
| BrilintaTicagrelor | 23 | $15,824 |
| VascepaIcosapent Ethyl | 14 | $4,633 |
| Atorvastatin Calcium | 202 | $2,811 |
| Metoprolol Succinate | 104 | $1,733 |
| Prasugrel Hcl | 19 | $1,293 |
| Carvedilol | 190 | $1,291 |
| Ranolazine ErRanolazine | 17 | $1,252 |
| Losartan Potassium | 87 | $1,184 |
| Rosuvastatin Calcium | 30 | $1,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $299 | $120,100137 claims |
| AstraZenecaFarxiga, Brilinta | $143 | $65,18279 claims |
| NovartisEntresto | $83 | $54,21944 claims |
| Johnson & JohnsonXarelto | $280 | $52,78857 claims |
| Boehringer IngelheimJardiance | $52 | $19,99120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Montgomery
- John KolawoleMontgomery$23K
- Taimoor HashimMontgomery$12K
- Thomas WoolMontgomery$8K
- Ashwini SharmaMontgomery$8K
- Gary RoubinBirmingham$157K
- Michael ButlerHuntsville$109K
- Pochana ReddyHuntsville$100K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
- John GallaMobile$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.